Journal of Thrombosis and Thrombolysis
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Andexanet alfa for treatment of factor Xa inhibitor-related acute major bleeding
2019
-
A Review of Computed Tomography Pulmonary Angiograms in Three Teaching Hospitals: the rise of Sub-Segmental Pulmonary Emboli
2013
-
Reversal of oral direct thrombin and factor Xa inhibitors: a systematic review
2013
-
Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure
2011
-
Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin
2008
-
The clinical consequence of subtherapeutic anticoagulation: the low INR study (LINeRS)
2008
-
Vitamin K for the Treatment of Asymptomatic Coagulopathy Associated with Oral Anticoagulant Therapy
2003
-
Heparin-induced thrombocytopenia and its treatment.
2000
-
Acute myocardial infarction in Canada: New epidemiologic insights on incidence, therapy, and risk
1996
-
Factor XIa inhibition as a therapeutic strategy for atherothrombosis
2024
-
The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review.
57:630-637.
2024
-
Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min.
55:355-364.
2023
-
Efficacy and safety of pre-operative insertion of inferior vena cava filter in patients undergoing bariatric surgery: a systematic review.
54:502-523.
2022
-
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum.
54:197-210.
2022
-
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves.
53:697-707.
2022
-
Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.
53:74-82.
2022
-
Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study.
51:561-570.
2021
-
Barriers and facilitators to optimal oral anticoagulant management: a scoping review.
50:697-714.
2020
-
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE.
50:267-277.
2020
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
50:20-29.
2020
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
50:12-19.
2020
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
50:1-11.
2020
-
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
46:339-345.
2018
-
Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada.
46:310-315.
2018
-
Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil.
45:578-587.
2018
-
Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study.
45:557-561.
2018
-
Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study.
45:486-495.
2018
-
Do telehealth interventions improve oral anticoagulation management? A systematic review and meta-analysis.
45:325-336.
2018
-
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
45:225-233.
2018
-
Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers.
45:180-185.
2018
-
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
43:484-489.
2017
-
Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
43:291-301.
2017
-
Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial.
42:336-339.
2016
-
Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis.
42:90-98.
2016
-
Erratum to: Guidance for the treatment of deep vein thrombosis and pulmonary embolism.
41:548-548.
2016
-
Occurrence and predictors of recurrence after a first episode of acute venous thromboembolism: population-based Worcester Venous Thromboembolism Study.
41:525-538.
2016
-
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
41:374-383.
2016
-
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia.
41:154-164.
2016
-
Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.
41:92-128.
2016
-
Guidance for the treatment of deep vein thrombosis and pulmonary embolism.
41:32-67.
2016
-
The epidemiology of venous thromboembolism.
41:3-14.
2016
-
Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves.
40:430-436.
2015
-
Patient-reported health preferences of anticoagulant-related outcomes.
40:268-273.
2015
-
A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal.
40:231-239.
2015
-
A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.
39:443-451.
2015
-
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.
39:427-433.
2015
-
Anticoagulation therapy in 2015: where we are and where we are going.
39:264-272.
2015
-
Aspirin in secondary prevention of recurrent venous thromboembolism.
39:392-394.
2015
-
Clinical significance and management of subsegmental pulmonary embolism.
39:311-314.
2015
-
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
39:23-34.
2015
-
Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.
39:60-67.
2015
-
Design of the rivaroxaban for heparin-induced thrombocytopenia study.
38:485-492.
2014
-
Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices.
37:435-442.
2014
-
Antiplatelet therapy in prevention of cardio- and venous thromboembolic events.
37:362-371.
2014
-
Reversal of target-specific oral anticoagulants.
36:195-202.
2013
-
Medical prophylaxis: the value of an “opt in” policy.
35:368-370.
2013
-
Proceedings of the 12th national conference on anticoagulant therapy.
35:303-303.
2013
-
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?.
35:295-301.
2013
-
Erratum to: Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
35:130-130.
2013
-
Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review.
35:67-80.
2013
-
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
34:429-436.
2012
-
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil.
34:143-163.
2012
-
Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.
33:412-415.
2012
-
Isolated calf deep vein thrombosis in the community setting: the Worcester Venous Thromboembolism study.
33:211-217.
2012
-
Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial.
33:88-94.
2012
-
Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study.
32:378-385.
2011
-
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil.
32:242-266.
2011
-
The clinical impact of bleeding during oral anticoagulant therapy.
31:419-423.
2011
-
Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction.
30:434-440.
2010
-
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
30:127-132.
2010
-
Combined warfarin–aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it?.
29:208-213.
2010
-
Update on heparin: what do we need to know?.
29:199-207.
2010
-
Using low molecular weight heparin in special patient populations.
29:233-240.
2010
-
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study.
28:401-409.
2009
-
Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs.
28:366-380.
2009
-
Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial.
28:266-268.
2009
-
Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial.
28:269-269.
2009
-
Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin.
24:93-97.
2007
-
Long-term trends in the use of coronary reperfusion strategies in acute myocardial infarction: a community-wide perspective.
23:163-171.
2007
-
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
23:229-236.
2007
-
Paper-based dosing algorithms for maintenance of warfarin anticoagulation.
23:195-198.
2007
-
Heparin resistance in acute coronary syndromes.
23:93-100.
2007
-
Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study.
22:31-38.
2006
-
Perioperative Anticoagulation for Patients with Mechanical Heart Valves: A Survey of Current Practice.
18:199-203.
2004
-
Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065a—A Selective and Direct Factor Xa Inhibitor.
18:193-197.
2004
-
The Effect of Temperature Variation In Vitro on Platelet-Leukocyte Interactions and Individual Prothrombotic Potential.
18:19-23.
2004
-
Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor..
15:19-23.
2003
-
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance..
14:123-129.
2002
-
Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trials..
12:289-295.
2001
-
New anticoagulant drugs..
12:7-17.
2001
-
Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review..
11:127-136.
2001
-
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization..
9:223-228.
2000
-
Heparin-induced thrombocytopenia: patient profiles and clinical manifestations..
10:21-25.
2000
-
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes..
10:69-76.
2000
-
Key references: Antiphospholipid antibody syndrome..
9:129-130.
2000
-
Key references: Protein C, protein S, and antithrombin deficiencies..
9:127-127.
2000
-
Laboratory testing for heparin-induced thrombocytopenia..
10:35-45.
2000
-
Diagnosis and management of inherited and acquired thrombophilias..
7:91-104.
1999
-
Guidelines for the Management of Patients with Acute Myocardial Infarction.
5:73-81.
1998
-
Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine..
5:215-229.
1998
-
Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins..
4:197-205.
1997
-
Current and Practical Management of Acute Myocardial Infarction..
4:375-396.
1997
-
Low-Molecular-Weight Heparin Should Replace Unfractionated Heparin for Treatment of Venous Thrombosis and Unstable Angina..
4:349-351.
1997
-
The Essence Trial: Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI: A Double-Blind, Randomized, Parallel-Group, Multicenter Study Comparing Enoxaparin and Intravenous Unfractionated Heparin: Methods and Design..
4:271-274.
1997
-
The Prothrombinase Complex: Assembly and Function..
4:357-364.
1997
-
Thrombolytic Therapy in Acute Myocardial Infarction: Management Algorithms..
4:397-413.
1997
-
Current approach to antithrombotic therapy: An abbreviated reference for practicing clinicians.
3:307-325.
1996
-
New therapeutic opportunities for heparins: What does low molecular weight heparin offer?.
3:145-149.
1996
-
Current references: Thromboembolism in congestive cardiomyopathy.
2:251-253.
1995
-
Issues regarding the use of heparin following streptokinase therapy.
2:5-10.
1995
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)